Spruce Biosciences Announces Acceptance of Abstract for Presentation at ENDO 2022 Annual Conference
May 31 2022 - 8:00AM
Business Wire
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage
biopharmaceutical company focused on developing and commercializing
novel therapies for rare endocrine disorders with significant unmet
medical need, today announced that a submitted abstract was
accepted for poster presentation at the 104th Annual Meeting of the
Endocrine Society (ENDO 2022) taking place June 11-14, 2022, in
Atlanta, GA. In a recorded presentation, the company will highlight
results from a recent survey of individuals living with congenital
adrenal hyperplasia (CAH) to assess their perceptions around
glucocorticoid treatment regimens and glucocorticoid-associated
side effects.
Details are as follows:
Title: (P079) A Survey of Patients Living with CAH
Assessing Their Perceptions on Glucocorticoid Regimen and
Glucocorticoid-Associated Side Effects Session Date &
Time: 1:00p.m. - 3:00p.m. ET on June 11, 2022 Presenter:
Dr. Chris N. Barnes Authors: Dr. Chris N. Barnes, Dr. Rosh
Dias, Melodie Feather and Nina Sherpa-Pine
The poster will be on display during the conference in ENDO
2022's virtual poster hall starting on June 11, at 10:00 a.m. ET.
Access more information about ENDO 2022 at
https://endo2022.endocrine.org.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company
focused on developing and commercializing novel therapies for rare
endocrine disorders with significant unmet medical need. Spruce is
initially developing its wholly-owned product candidate,
tildacerfont, as the potential first non-steroidal therapy for
patients suffering from classic congenital adrenal hyperplasia
(CAH). Classic CAH is a serious and life-threatening disease with
no known novel therapies approved in approximately 50 years. Spruce
is also developing tildacerfont for women suffering from polycystic
ovary syndrome (PCOS) with primary adrenal androgen excess. To
learn more, visit www.sprucebiosciences.com and follow us on
Twitter @Spruce_Bio, LinkedIn, Facebook and YouTube.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220531005203/en/
Media Contact Will Zasadny Canale Communications (619)
961-8848 will.zasadny@canalecomm.com
media@sprucebiosciences.com
Investors Xuan Yang Solebury Trout (415) 971-9412
xyang@soleburytrout.com investors@sprucebiosciences.com
Spruce Biosciences (NASDAQ:SPRB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Spruce Biosciences (NASDAQ:SPRB)
Historical Stock Chart
From Apr 2023 to Apr 2024